In this article, we will take a look at some of the best mid-cap stocks that are currently offering at least 100% upside potential to investors. On June 13, CNBC reported that U.S. equities rose as investor sentiment improved amid optimism surrounding a potential peace agreement between the United States and Iran, along with a strong demand for new stock offerings.
The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average all ended the week higher, while oil prices declined as markets monitored developments on a possible agreement that could include lifting oil sanctions and reopening the Strait of Hormuz.
Strong demand for new public offerings has also bolstered investor confidence. According to Mark Klein, CEO and president of SuRo Capital, SpaceX’s IPO could serve as a key sign of future IPO activity, as more businesses think about going public. Several technology stocks posted gains during the session, while Jeff Kilburg, CEO of KKM Financial, said the AI theme continues to strengthen despite recent market volatility.
The strong market performance also reflected continued interest in growth-oriented sectors, particularly technology and artificial intelligence-related investments. With that background, let’s explore our 10 Best Mid-Cap Stocks That Could Double Your Money.
Photo by Mizuno K on pexels
Our Methodology
To identify relevant stocks for this article, we screened U.S.-listed companies with market capitalizations between $2 billion and $10 billion. Also, we only shortlisted stocks with at least 100% upside potential, according to consensus, as of the June 12 close. Finally, we selected 10 stocks with the highest upside and ranked them in ascending order.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. Uranium Energy Corp. (NYSE:UEC)
Uranium Energy Corp. (NYSE:UEC) is one of the 10 best mid-cap stocks that could double your money.
On June 9, Amir Adnani, President and CEO of Uranium Energy Corp., stated that the company achieved a number of noteworthy milestones during the quarter that reflect on its operational execution capabilities, as well as the size and caliber of its asset portfolio. It initiated production at Burke Hollow, the biggest greenfield ISR uranium project in the U.S. in well over a decade. This is a significant step towards increasing the amount of uranium available domestically.
In order to complement its methodical and controlled growth approach, production for the Christensen Ranch project also began, following the recently installed header houses, while further capacity expansion initiatives are underway. Simultaneously, the company finished engineering programs and delineation drilling at Ludeman, as its next planned ISR uranium facility.
With substantial liquidity, no liability, a sound balance sheet, and an expanding uranium inventory that boosts the implementation of a long-term strategy, the company continues to be in a very good financial position. The management’s decision to maintain inventory levels this quarter is an example of how their unhedged approach allows for flexibility in sales decisions.
These achievements align with a growing national emphasis on nuclear energy, such as DOE’s “Nuclear Dominance – 3 by 33” campaign, which aims to bolster the country’s domestic nuclear fuel supply chain.
Uranium Energy Corp. is involved in the pre-extraction, extraction, exploration, and processing of titanium and uranium concentrate properties. The company has operations across Canada, the U.S., and the Republic of Paraguay.
9. Figure Technology Solutions Inc. (NASDAQ:FIGR)
Figure Technology Solutions Inc. (NASDAQ:FIGR) is one of the 10 best mid-cap stocks that could double your money.
On June 4, a funding agreement between Figure Technology Solutions Inc. and Cross River Bank, a provider of technology infrastructure with a focus on embedded financial solutions, was announced. Cross River’s Principal Finance Group has agreed to spend up to $250 million on assets that will support Figure’s Crypto-Backed Loans initiative.
Crypto-backed lending provides many owners of digital assets with a more affordable financing option, according to Noah Cooper, CIO and Head of Capital Solutions Group at Cross River. Without having to sell cryptocurrency assets, the agreement gives Figure committed capital to provide USD liquidity to consumers. Digital assets can be used as collateral by borrowers without giving up ownership.
Cross River’s involvement, according to Figure’s Chief Capital Officer Todd Stevens, is proof of the company’s expansion and uptake. Both companies’ attempts to increase access to financial solutions connected to cryptocurrencies are further supported by the alliance. Stevens stated:
“With Crypto-Backed Loans, we’ve gone from a relatively new idea – to allow borrowing against a highly popular appreciated asset – and we’ve achieved rapid adoption while creating a model that others have followed. Cross River’s involvement is a major proof point underscoring our success so far, as well as our continued upward trajectory.”
Figure Technology Solutions Inc. is a financial technology company that deploys blockchain-based products and solutions. It offers an exchange for digital assets and credit (i.e., Figure Connect) and delivers a technology-enabled loan origination system paired with a distribution marketplace. The company also has a suite of blockchain-based solutions, such as trading, lending, and investing activities.
8. VNET Group Inc. (NASDAQ:VNET)
VNET Group Inc. (NASDAQ:VNET) is one of the 10 best mid-cap stocks that could double your money.
Back on May 27, while maintaining an Overweight rating and a $16 price target for the stock, Tom Tang from Morgan Stanley picked VNET Group Inc. as his top choice. The analyst claims that since a CATL affiliate was introduced, VNET’s issues related to the shareholders have been mostly fixed. Additionally, he mentioned that 500 megawatt MOUs have led to an increase in forward visibility. According to Tang, based on premium resources, VNET currently carries a first-mover advantage.
Later on June 9, Chinese cloud service providers GDS Holdings Limited (NASDAQ:GDS) and VNET Group Inc. saw increases in their US depositary receipts of approximately 7% and 9%, respectively, as reported by Bloomberg. The report highlighted that China is getting ready to invest $295 billion in data center development nationwide.
A national network of interconnected data centers is now being planned by government agencies, such as the National Development and Reform Commission. According to the sources, Chinese vendors would provide about 80% of the technology, while state-owned companies like China Mobile and China Telecom are anticipated to run the majority of the infrastructure.
VNET Group Inc. is an investment holding company based in China that offers interconnectivity and managed hosting services. It also delivers managed retail and value-added solutions such as firewall, hybrid IT, server management, and standby servers. The company serves various segments such as IT, telecom, finance, gaming, and government entities.
7. Celsius Holdings Inc. (NASDAQ:CELH)
Celsius Holdings Inc. (NASDAQ:CELH) is one of the 10 best mid-cap stocks that could double your money.
On June 12, Bernstein began its coverage of Celsius Holdings Inc. with a price target of $44. An Outperform rating was assigned on the stock, which offers almost 55% upside based on the projected price target.
The firm made a notable mention of Alani Nu, which has the highest potential among the company’s brands. Bernstein also mentioned that potential worries about a drop in market share for the Celsius brand appear to be highly exaggerated.
As long as Alani keeps gaining market share, the firm thinks the portfolio can maintain its position in the United States. Bernstein argues that this will occur due to Alani’s exceptional brand equity, which is backed by the findings of their consumer survey.
Back on May 19, Jefferies maintained its Buy rating and a $71 price target on Celsius Holdings Inc., after analyst Kaumil Gajrawala held meetings with top company executives, including the Chief Executive Officer John Fieldly, Chief of Staff Toby David, and Chief Financial Officer Jarrod Langhans.
Gajrawala stated that recent business concerns appear to be linked with timing rather than being structural in nature, which makes them highly exaggerated. He noted that the company’s core brand, Alani, is now heading towards a new phase. He also acknowledged how the market seems to be underappreciating the brand, despite its strong momentum. He views the recent share price drop as a favorable buying opportunity for investors.
Celsius Holdings Inc. manufactures and distributes functional energy drinks, including hydration sticks, CELSIUS ESSENTIALS, and CELSIUS Hydration. It also offers nutrition and wellness products, and ready-to-drink energy beverages under Alani Nu, Rockstar, and CELSIUS brand names. It distributes its products through drug stores, food service locations, retail stores, distributors, and e-commerce platforms.
6. Karman Holdings Inc. (NYSE:KRMN)
Karman Holdings Inc. (NYSE:KRMN) is one of the 10 best mid-cap stocks that could double your money.
On May 29, Karman Holdings Inc. announced the initiation of an underwritten public offering consisting of 13.5 million shares of its common stock, which is being facilitated by specific selling stockholders.
This offering’s execution is still contingent upon current market and customary conditions. Additionally, it has been made clear that Karman is not selling any shares in this deal and will not receive any money from the sale. Rather, the selling stockholders will receive full net proceeds.
Additionally, Citigroup and Evercore ISI have been appointed to serve as the joint book-running managers for the offering.
Back on May 13, Evercore ISI maintained an Outperform rating on Karman Holdings Inc. while decreasing the target price from $125 to $100. Despite this downward adjustment, the stock still yields an attractive upside potential in excess of 101% at the current level. Despite the reduction in price target, the firm noted that the company’s first-quarter performance establishes a positive momentum for the remainder of the year.
Karman Holdings Inc. designs and sells mission-critical systems such as aerodynamic inter-stage systems, propulsion systems, payload protection, and deployment systems. It serves tactical missile and integrated defense systems, space and launch markets, and hypersonics and strategic missile defense.
5. Structure Therapeutics Inc. (NASDAQ:GPCR)
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best mid-cap stocks that could double your money.
On June 11, H.C. Wainwright reduced its price target on Structure Therapeutics Inc. from $100 to $70, which still leads to an adjusted upside potential of more than 61%. The firm upheld its Buy rating on the stock.
Source:unsplash
H.C. Wainwright noted that Retatrutide’s clean low-dose profile alongside Pfizer’s once-monthly injectable establishes a new benchmark within the identical mid-body mass index market that oral treatments are targeting. Consequently, the firm cited increasing competitive pressure as the primary reason for the price target reduction.
On June 6, Structure Therapeutics Inc. announced Phase 2b ACCESS trial results for aleniglipron in Nature Medicine. A lower 2.5 mg starting dose improved tolerability. Furthermore, weight loss persisted beyond 36 weeks, shaping the Phase 3 trials scheduled for the third quarter of 2026.
Patients actually kept shedding weight during the extension phase without hitting a plateau. According to Steering Committee Chair Dr. Julio Rosenstock, MD, this continuous weight loss makes the daily oral drug a highly unique option for patients.
Structure Therapeutics Inc. is involved in the development and marketing of novel oral small molecule therapies for the treatment of several chronic diseases with unmet medical needs. The company is currently working on several drug candidates, which include GSBR-1290, ACCG-2671, ACCG-3535, LTSE-2578, and ANPA-0073. Additionally, it also develops programs like the GCG and GIPR programs.
4. Vaxcyte Inc. (NASDAQ:PCVX)
Vaxcyte Inc. (NASDAQ:PCVX) is one of the 10 best mid-cap stocks that could double your money.
On June 3, Vaxcyte Inc. announced that the first participant was dosed in the Phase 1, first-in-human study evaluating VAX-A1. This is the company’s investigational prophylactic vaccine candidate for the prevention of disease caused by Group A Streptococcus in healthy adults aged 18 to 40 years.
The company anticipates reporting topline data from the study in the second half of 2027. The primary objective of the randomized, double-blind, placebo-controlled, dose-escalation, two-stage study is to assess the safety and tolerability of VAX-A1, while the secondary objective is to evaluate initial immunogenicity data.
Stage 1 will evaluate three dose levels compared to a placebo in approximately 12 adults. Following independent Data Safety Monitoring Board approval, Stage 2 will evaluate the same dose levels in approximately 68 adults.
Speaking about this development, Grant Pickering, CEO and Co-Founder of Vaxcyte, stated that initiation of the study represents an important milestone in addressing a significant global public health challenge with no approved vaccine. Furthermore, Jim Wassil, EVP and COO, noted that Group A Strep is responsible for a wide spectrum of diseases.
Vaxcyte Inc. is a company involved in the development of next-generation vaccines that offer protection against threatening bacterial diseases. Currently a clinical-stage company, Vaxcyte Inc. deploys innovative synthetic methods and advanced chemistry to produce complex, high-fidelity vaccines that contain enhanced immunological benefits.
3. Vera Therapeutics Inc. (NASDAQ:VERA)
Vera Therapeutics Inc. (NASDAQ:VERA) is one of the 10 best mid-cap stocks that could double your money.
On June 2, Vera Therapeutics, Inc. announced that it reached an agreement with the U.S. Food and Drug Administration regarding an accelerated timeline for its ORIGIN 3 eGFR analysis plan. This revised approach is intended to support the full regulatory approval of atacicept for adult patients suffering from IgA nephropathy (IgAN).
The third quarter of 2026 is when the eGFR findings are anticipated to be released, while in the fourth quarter of 2026, Vera plans to file a supplemental Biologics License Application (sBLA) for complete regulatory approval, contingent on the results of the data. Additionally, the modified regulatory approach was supported by past eGFR data from the company’s ORIGIN Phase 2b clinical trial.
Marshall Fordyce, M.D., the Founder and CEO of Vera Therapeutics, noted that this modification highlights the medication’s potential to be the first licensed treatment for adult IgAN patients that targets both BAFF and APRIL. He also mentioned the possibility of accelerating full market approval by advancing the data analysis timeline.
Vera Therapeutics Inc. is a late-stage clinical biotechnology company that addresses immunological conditions. The company develops and commercializes transformative treatments for serious diseases such as immunoglobulin A nephropathy. It is currently developing MAU868, which is a monoclonal antibody for BK viremia infections in transplant patients.
2. Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX)
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 best mid-cap stocks that could double your money. Based on consensus estimates, as of June 12, the stock offers more than 159% upside potential at the current level.
On June 11, Leerink analyst Joseph Schwartz maintained an Outperform rating on Crinetics Pharmaceuticals Inc. following a regulatory setback for a potential rival company. Camurus received a complete response letter regarding its application for Oclaiz, a targeted treatment for acromegaly.
Camurus made it clear that observations from a September 2024 cGMP inspection at a third-party manufacturing site are the direct cause of this rejection. Notably, this marks the second such rejection for this specific application.
According to the analyst, Crinetics Pharmaceuticals will benefit greatly from this development. He explained that during the crucial initial phases of Palsonify’s commercial deployment, the complete response letter effectively prevents a potential rival from entering the U.S. market.
As a result, it won’t have to deal with pressure from a new branded competitor entering the acromegaly market. Additionally, this provides Crinetics with more time to aggressively build physician familiarity, enhance payer onboarding processes, and convert early patient interest.
Crinetics Pharmaceuticals Inc. is engaged in developing and marketing innovative treatments for rare endocrine diseases and endocrine-related tumors. The company offers a range of therapies that are currently in different stages of clinical trials. These include Paltusotine, Atumelnant, CRN09682, oral GLP-1, and GIP nonpeptide.
1. Viking Therapeutics Inc. (NASDAQ:VKTX)
Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 best mid-cap stocks that could double your money.
On May 28, Lake Street assigned a Buy rating to Viking Therapeutics Inc. while setting a price target at $89. This leads to an upside potential of more than 211% at the prevailing level.
According to the firm, this stance is driven by the market opportunity for VK2735, the company’s lead clinical asset for obesity. VK2735 is projected to generate approximately $3 billion in risk-adjusted worldwide sales by the year 2040. Additionally, the firm noted the potential for further financial upside stemming from the company’s earlier-stage pipeline assets.
On May 27, Truist published a report on Viking Therapeutics Inc. with a Buy rating and a price target of $83, indicating a 191% upside. The firm highlighted the company as a distinct competitor within a crowded and highly aggressive obesity treatment market.
The company effectively addresses two major hurdles found in existing and emerging treatments, which include long-term patient compliance and rapid time to efficacy, pointing to the achievement of 14.7% weight loss within 13 weeks without hitting a plateau.
Furthermore, Truist emphasized that by offering both the oral and subcutaneous delivery options, the company enables a continuous care model with adaptable dosing and flexible titration. This versatility allows for greater clinical personalization while helping to reduce gastrointestinal side effects.
Viking Therapeutics Inc. specializes in metabolic and endocrine disorder therapies. As a clinical-stage biopharmaceutical company, they direct their research efforts towards small-molecule drugs to cure obesity, fatty liver, and diabetes.
